#4655
A novel nonpeptide drug conjugate (NDC) for the treatment of somatostatin receptor 2-expressing tumours
Introduction:
Somatostatin receptor 2 (SST2) is an established target for the treatment of NETs and potentially other solid tumours.
Conference:
Presenting Author:
Authors:
Zhao J,
Sturchler E,
Yang B,
Chen M,
Tang Y,
Keywords:
somatostatin,
solid tumour,
drug conjugate,
internalisation,
cytotoxicity,
#4282
A first-in-human phase I trial with antibody drug conjugate ADCT-701 in neuroendocrine tumours and carcinomas
Introduction:
Neuroendocrine neoplasms (NENs) consist of neuroendocrine tumours and neuroendocrine carcinomas, which are rare malignancies found in various anatomical sites, including the gastrointestinal tract, pancreatic islets, lungs, and adrenal glands. Poorly differentiated NECs are classified as high-grade carcinomas that bear resemblance to small-cell lung cancer; however, these patients experience a high risk of relapse and demonstrate a limited response to additional systemic therapies. Adrenocortical carcinoma (ACC) is another rare cancer and currently, no targeted therapies have demonstrated significant effectiveness for this condition. Preclinical investigations have indicated that Delta-like non-canonical notch ligand 1 (DLK1) is expressed in various neuroendocrine neoplasms, including ACC, SCLC, neuroblastoma, pheochromocytoma, and paraganglioma.
Conference:
Presenting Author:
Del Rivero J
Authors:
Del Rivero J,
Glod J,
Magee T,
Cooper K,
Rivero A,
Keywords:
NEN,
NEC,
NET,
ACC,
ADC,
ADCT-701,
#2142
Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Introduction:
Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Mansfield A
Authors:
Mansfield A,
Aggarwal R,
Beltran H,
Farago A,
Hann C,
Keywords:
Rovalpituzumab tesirine,
DLL3,
neuroendocrine tumors,
antibody-drug conjugate,
